That is an important question, and there are two main reflections. One is that we need to pursue the work that we are undertaking with the MHRA on the rigour with which devices are approved for use in our healthcare system. That work involves devices across the piece, whether they are mesh or a hip joint or something else, and is to ensure that we have a rigour in that area that is comparable to the rigour for drug trials and approved drug use in our health service.
The other reflection is the importance of a consistent pathway and making sure that our patients, whatever the circumstances and whatever their condition, have the maximum amount of information in order to make an informed decision and choice. That was reflected by the work of the citizens panel that the chief medical officer ran. I am sure that members have seen its report about the importance of genuinely shared decision making and making sure that an individual patient has all the information that they need and is given the opportunity to ask questions and to return to those questions.
Those are the two main reflections, which apply widely across our health service, rather than simply to this issue.